Safety of Steroids in Severe Community-acquired Pneumonia

Overview

Journal Eur Respir Rev

Date 2025 Jan 8

PMID 39778921

Authors

Federica Viola Piedepalumbo

Ana Motos

Francesco Blasi

Antoni Torres

Affiliations

Soon will be listed here.

Abstract

The systemic use of corticosteroids for patients with severe community-acquired pneumonia (sCAP) remains controversial in clinical practice, particularly in terms of the safety profile of these drugs. This narrative review aims to analyse the available literature data concerning the safety of short-term steroid use in the treatment of sCAP, while also highlighting potential future research directions. Several trials and meta-analyses have evaluated corticosteroid therapy as an adjuvant treatment for sCAP, yielding heterogeneous results regarding its efficacy and safety. Despite the wide variability in results, it is generally accepted that steroids are not associated with a significant risk of healthcare-associated infections, gastrointestinal bleeding or acute kidney injury in patients with sCAP in the short term. Nevertheless, such drugs are linked to hyperglycaemia, necessitating regular monitoring and appropriate management. The influence of steroids on long-term outcomes and their potential risks in viral sCAP still needs to be investigated.

References

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J . Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7):677-86. DOI: 10.1001/jama.2015.88. View

Leistner R, Schroeter L, Adam T, Poddubnyy D, Stegemann M, Siegmund B . Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients. Crit Care. 2022; 26(1):30. PMC: 8796178. DOI: 10.1186/s13054-022-03902-8. View

Dequin P, Meziani F, Quenot J, Kamel T, Ricard J, Badie J . Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023; 388(21):1931-1941. DOI: 10.1056/NEJMoa2215145. View

Torres A, Motos A, Cilloniz C, Ceccato A, Fernandez-Barat L, Gabarrus A . Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study. Intensive Care Med. 2022; 48(7):850-864. PMC: 9211796. DOI: 10.1007/s00134-022-06726-w. View

Meijvis S, Hardeman H, Remmelts H, Heijligenberg R, Rijkers G, van Velzen-Blad H . Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011; 377(9782):2023-30. DOI: 10.1016/S0140-6736(11)60607-7. View

Merkofer F, Struja T, Delfs N, Spagnuolo C, Hafner J, Kupferschmid K . Glucose control after glucocorticoid administration in hospitalized patients - a retrospective analysis. BMC Endocr Disord. 2022; 22(1):8. PMC: 8734262. DOI: 10.1186/s12902-021-00914-3. View

Iqbal N, Irfan M, Siddiqui F, Arshad V, Zuabairi A . Effects of systemic steroids on patients with community-acquired pneumonia: Observational study from a tertiary care hospital of a developing country. Respir Investig. 2020; 58(6):495-501. DOI: 10.1016/j.resinv.2020.05.004. View

Blum C, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I . Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015; 385(9977):1511-8. DOI: 10.1016/S0140-6736(14)62447-8. View

10.

Fernandez-Serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratala J, Fernandez-Aguera A . Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011; 15(2):R96. PMC: 3219361. DOI: 10.1186/cc10103. View

11.

Katsuyama T, Sada K, Namba S, Watanabe H, Katsuyama E, Yamanari T . Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015; 108(2):273-9. DOI: 10.1016/j.diabres.2015.02.010. View

12.

Sprung C, Annane D, Keh D, Moreno R, Singer M, Freivogel K . Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008; 358(2):111-24. DOI: 10.1056/NEJMoa071366. View

13.

Boumpas D, Chrousos G, Wilder R, Cupps T, Balow J . Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993; 119(12):1198-208. DOI: 10.7326/0003-4819-119-12-199312150-00007. View

14.

Gangneux J, Dannaoui E, Fekkar A, Luyt C, Botterel F, de Prost N . Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2021; 10(2):180-190. PMC: 8626095. DOI: 10.1016/S2213-2600(21)00442-2. View

15.

Annane D, Pastores S, Rochwerg B, Arlt W, Balk R, Beishuizen A . Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med. 2017; 43(12):1751-1763. DOI: 10.1007/s00134-017-4919-5. View

16.

Mangos G, Whitworth J, Williamson P, Kelly J . Glucocorticoids and the kidney. Nephrology (Carlton). 2004; 8(6):267-73. DOI: 10.1111/j.1440-1797.2003.00215.x. View

17.

Martin-Loeches I, Nagavci B, Torres A . Guidelines for the management of severe community-acquired pneumonia: one confusing recommendation. Author's reply. Intensive Care Med. 2023; 49(10):1261-1262. DOI: 10.1007/s00134-023-07184-8. View

18.

Kim S, Hong S, Yun S, Choi W, Ahn J, Lee Y . Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. Am J Respir Crit Care Med. 2011; 183(9):1207-14. DOI: 10.1164/rccm.201101-0110OC. View

19.

Martinek J, Hlavova K, Zavada F, Seifert B, Rejchrt S, Urban O . "A surviving myth"--corticosteroids are still considered ulcerogenic by a majority of physicians. Scand J Gastroenterol. 2010; 45(10):1156-61. DOI: 10.3109/00365521.2010.497935. View

20.

Venkatesh B, Finfer S, Cohen J, Rajbhandari D, Arabi Y, Bellomo R . Adjunctive Glucocorticoid Therapy in Patients with Septic Shock. N Engl J Med. 2018; 378(9):797-808. DOI: 10.1056/NEJMoa1705835. View